Key result
Transgenic mouse hearts with the E54K mutation showed an approximately 40% decrease in tropomyosin phosphorylation compared to non-transgenic hearts.
Population
Transgenic mouse hearts with tropomyosin mutant (Glu54Lys) linked to dilated cardiomyopathy
Comparison
Tropomyosin mutant (Glu54Lys) vs Non-transgenic mouse hearts
Design
Preclinical
Authors
Loading...
May link E54K mutation to DCM via reduced phosphorylation; hypothesis-generating in mice, needs human validation.
Effect estimate: approximately 40% decrease
The study provides the first evidence that altered phosphorylation of tropomyosin may be a significant factor linking the E54K mutation to dilated cardiomyopathy.
Warren et al. (2007) studied Dilated cardiomyopathy. E54K mutation (transgenic mouse model) vs. Non-transgenic mouse hearts was evaluated on Tropomyosin (Tm) phosphorylation (approximately 40% decrease). Transgenic mouse hearts with the E54K mutation showed an approximately 40% decrease in tropomyosin phosphorylation compared to non-transgenic hearts.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: